TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06625593: A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Pati

Sponsor: BeOne Medicines · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 168 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT06625593 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06625593 Rescue Dossier →